共查询到20条相似文献，搜索用时 15 毫秒
1.
Signe Foghsgaard MD Louise Vedtofte MSc Emilie S. Andersen MD Emilie Bahne MD Camilla Andreasen MD Anne L. Sørensen MSc Julie L. Forman MSc Elisabeth R. Mathiesen MD Jens A. Svare MD Tine D. Clausen MD Peter Damm MD Jens J. Holst MD Filip K. Knop MD Tina Vilsbøll MD 《Diabetes, obesity & metabolism》2024,26(1):201-214
2.
Sho Furusawa MD Hiroshi Nomoto MD Hiroki Yokoyama MD Yuka Suzuki MD Atsushi Tsuzuki MD Kiyohiko Takahashi MD Aika Miya MD Hiraku Kameda MD Kyu Yong Cho MD Jun Takeuchi MD So Nagai MD Shinji Taneda MD Yoshio Kurihara MD Akinobu Nakamura MD Tatsuya Atsumi MD SWITCH-SEMA study group 《Diabetes, obesity & metabolism》2024,26(3):961-970
3.
Linong Ji;Yibing Lu;Zewei Shen;Ping Hu;Wenyan Liu;Qiu Zhang;Bimin Shi; 《Diabetes, obesity & metabolism》2024,26(11):5312-5324
To investigate the impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg in participants with type 2 diabetes (T2D) from the SUSTAIN China trial. 相似文献
4.
Jeff Unger MD Dale C. Allison MD Margit Kaltoft MD Kavitha Lakkole MBA Jayant K. Panda MD Chethana Ramesh MSc Mehmet Sargin MD Elena Smolyarchuk MD Melissa Twine BS Benjamin Wolthers MD Gizem Yarimbas MSc Marouan Zoghbi MD the LIRA-PRIME investigators 《Diabetes, obesity & metabolism》2022,24(2):204-211
5.
Christian Anholm MD Preman Kumarathurai PhD Amirsalar Samkani MD Lene R. Pedersen PhD Raymond C. Boston PhD Olav W. Nielsen DMSci Ole P. Kristiansen DMSci Mogens Fenger DMSci Sten Madsbad DMSci Ahmad Sajadieh DMSci Steen B. Haugaard DMSci 《Diabetes, obesity & metabolism》2019,21(8):2012-2016
Elevated levels of non-esterified fatty acids (NEFA) play a role in insulin resistance, impaired beta-cell function and they are a denominator of the abnormal atherogenic lipid profile that characterizes obese patients with type 2 diabetes (T2DM). We hypothesized that the GLP-1 receptor agonist liraglutide, in combination with metformin, would reduce lipolysis. In a randomized, double-blind, placebo-controlled, cross-over trial, 41 T2DM patients with coronary artery disease were randomized and treated with liraglutide-metformin vs placebo-metformin during 12- + 12-week periods with a wash-out period of at least 2 weeks before and between the intervention periods. NEFA kinetics were estimated using the Boston Minimal Model of NEFA metabolism, with plasma NEFA and glucose levels measured during a standard 180-minute frequently sampled intravenous glucose tolerance test. Liraglutide-metformin reduced estimates of lipolysis. Furthermore, placebo-metformin increased estimates of lipid oxidation, while treatment with liraglutide eliminated this effect. We conclude that liraglutide exerts a clinically relevant reduction in estimates of lipolysis and lipid oxidation which is explained, in part, by improved insulin secretion, as revealed by an intravenous glucose tolerance test. 相似文献
6.
7.
Maria S. Svane PhD Helle H. Johannesen MD Christoffer Martinussen PhD Kirstine N. Bojsen-Møller PhD Martin Lundsgaard Hansen PhD Adam E. Hansen PhD Carolyn F. Deacon DMSci Bolette Hartmann PhD Sune H. Keller PhD Thomas L. Klausen MSc Annika Loft PhD Andreas Kjaer DMSci Sten Madsbad DMSci Johan Löfgren MD Jens J. Holst DMSci Nicolai J. Wewer Albrechtsen PhD 《Diabetes, obesity & metabolism》2020,22(10):1837-1846
8.
Henriette H. Nerild MD Andreas Brønden MD Ida M. Gether MD Pernille H. Hellmann MD Mille Baekdal MD Matthew P. Gillum PhD Jens S. Svenningsen Bolette Hartmann PhD Naveen Rathor MD Hanna Angelene Kudiyanur Muniraju MSc Jens F. Rehfeld MD Jens J. Holst MD Tina Vilsbøll MD David P. Sonne MD Filip K. Knop MD 《Diabetes, obesity & metabolism》2023,25(6):1632-1637
Aim
Liraglutide treatment is associated with gallbladder-related disorders and has been shown to delay postprandial gallbladder refilling. The gut hormones cholecystokinin (CCK), fibroblast growth factor 19 (FGF19) and glucagon-like peptide 2 (GLP-2), are known to regulate gallbladder motility and may be implicated in gallbladder-related disorders associated with liraglutide treatment.Materials and Methods
In a double-blind, 12-week trial, 52 participants [50% male, age 47.6 ± 10.0 years, body mass index 32.6 ± 3.4 kg/m2 (mean ± standard deviation)] with obesity were randomized 1:1 to once-daily subcutaneous liraglutide (escalated from 0.6 mg to 3.0 mg once-daily) or placebo. During liquid meal tests performed at baseline, after the first dose and following 12 weeks of treatment, we evaluated postprandial gallbladder dynamics and plasma responses of CCK, FGF19 and GLP-2.Results
Liraglutide reduced postprandial FGF19 after the first dose [area under the curve (AUC)0-240 min 24.8 vs. 48.0 min × ng/ml, treatment ratio (TR) (95% confidence interval) 0.52 (0.39; 0.69)] and following 12 weeks of treatment [AUC0-240 min 33.7 vs. 48.5 ng/ml × min, TR 0.69 (0.52; 0.93)]. Liraglutide also reduced postprandial GLP-2 responses (AUC0-240 min 3650 vs. 4894 min × pmol/L, TR 0.75 (0.62; 0.90)] following the first dose as well as after 12 weeks [AUC0-240 min 3760 vs. 4882 min × pmol/L, TR 0.77 (0.60; 0.99)]. Liraglutide increased postprandial responses of CCK after the first dose [AUC0-240 min 762 vs. 670 min × pmol/L; TR 1.14 (0.97; 1.33)] and following 12 weeks of treatment [AUC0-240 min 873 vs. 628 min × pmol/L; TR 1.39 (1.12; 1.73)].Conclusion
Compared with placebo, treatment with liraglutide decreased postprandial FGF19 and GLP-2 concentrations and increased postprandial CCK concentrations, which may explain the delayed postprandial gallbladder refilling observed in individuals with obesity treated with liraglutide. 相似文献9.
Yuka Takahashi MD Hiroshi Nomoto MD Hiroki Yokoyama MD Yoshinari Takano MD So Nagai MD Atsushi Tsuzuki MD Kyu Yong Cho MD Aika Miya MD Hiraku Kameda MD Jun Takeuchi MD Shinji Taneda MD Yoshio Kurihara MD Tatsuya Atsumi MD Akinobu Nakamura MD Hideaki Miyoshi MD SWITCH-SEMA study group 《Diabetes, obesity & metabolism》2023,25(6):1503-1511
10.
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub‐analysis of a randomized,placebo‐controlled,double‐blind,crossover trial 
下载免费PDF全文
下载免费PDF全文 Bernt Johan von Scholten MD Frederik Persson MD DMSc Signe Rosenlund MD Jesper Eugen‐Olsen PhD Tomasz Pielak BSc Jens Faber MD DMSc Tine W. Hansen MD PhD Peter Rossing MD DMSc 《Diabetes, obesity & metabolism》2017,19(6):901-905
We assessed the effects of liraglutide treatment on five cardiovascular risk biomarkers, reflecting different pathophysiology: tumour necrosis factor (TNF)‐α; soluble urokinase plasminogen activator receptor (suPAR); mid‐regional pro‐adrenomedullin (MR‐proADM); mid‐regional pro‐atrial natriuretic peptide (MR‐proANP); and copeptin, in people with type 2 diabetes with albuminuria. In a randomized, double‐blind, placebo‐controlled, crossover trial we enrolled people with type 2 diabetes and persistent albuminuria (urinary albumin‐to‐creatinine ratio [UACR] >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2. Participants received liraglutide (1.8 mg/d) and matched placebo for 12 weeks, in random order. The primary endpoint was change in albuminuria; this was a prespecified sub‐study. A total of 32 participants were randomized, of whom 27 completed the study. TNF‐α level was 12% (95% confidence interval [CI] 3; 20) lower after liraglutide treatment compared with placebo (P = .012); MR‐proADM level was 4% (95% CI 0; 8) lower after liraglutide treatment compared with placebo (P = .038), and MR‐proANP level was 13% (95% CI 4; 21) lower after liraglutide treatment compared with placebo (P = .006). In the present study, we showed anti‐inflammatory effects of liraglutide treatment, reflected in reductions in levels of TNF‐α and MR‐proADM, while the reduction in MR‐proANP levels may represent a clinically relevant benefit with regard to heart failure. 相似文献
11.
12.
Thomas F. Dejgaard;Christian S. Frandsen;Urd Kielgast;Joachim Størling;Anne J. Overgaard;Maria S. Svane;Markus Harboe Olsen;Birger Thorsteinsson;Henrik U. Andersen;Thure Krarup;Jens J. Holst;Sten Madsbad; 《Diabetes, obesity & metabolism》2024,26(11):4905-4915
To test the effect of the glucagon-like peptide-1 receptor agonist, liraglutide, on residual beta-cell function in adults with newly diagnosed type 1 diabetes. 相似文献
13.
Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials 下载免费PDF全文
下载免费PDF全文 J. Ard A. Cannon C. E. Lewis H. Lofton T. Vang Skjøth B. Stevenin X. Pi‐Sunyer 《Diabetes, obesity & metabolism》2016,18(4):430-435
The efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to diet and exercise, was evaluated in racial subgroups. This post hoc analysis of pooled data from five double‐blind randomized, placebo‐controlled trials was conducted in 5325 adults with either a body mass index (BMI) ≥27 kg/m2 plus ≥1 comorbidity or a BMI ≥30 kg/m2. Statistical interaction tests evaluated possible treatment effect differences between racial subgroups: white (4496, 84.4%), black/African‐American (550, 10.3%), Asian (168, 3.2%) and other (111, 2.1%). Effects of liraglutide 3.0 mg on weight loss, associated metabolic effects and safety profile were generally consistent across racial subgroups. All achieved statistically significant mean weight loss at end‐of‐treatment with liraglutide 3.0 mg versus placebo: white 7.7% versus 2.3%, black/African‐American 6.3% versus 1.4%, Asian 6.3% versus 2.5%, other 7.3% versus 0.49%. Treatment effects on weight and cardiovascular risk markers generally showed no dependence on race (interaction test p > 0.05). Adverse events were similar across racial subgroups. 相似文献
14.
Rie Yazawa MD Masahiro Ishida MA Yesilda Balavarca PhD Anita M. Hennige MD 《Diabetes, obesity & metabolism》2023,25(7):1973-1984
Aim
To report a Phase I study of subcutaneous glucagon receptor (GCGR)/glucagon-like peptide-1 receptor (GLP-1R) dual agonist BI 456906 versus placebo in healthy Japanese men with overweight/obesity.Materials and methods
We investigated multiple rising doses of BI 456906 escalated over 16 weeks (maximum doses: 1.8 mg once weekly [dose group {DG} 1], 4.8 mg once weekly [DG 2] and 2.4 mg twice weekly [DG 3]) in Japanese men with a body mass index of 23 to 40 kg/m2.Results
Thirty-six participants were treated (n = 9 per DG and placebo). Overall, 10 participants (37.0%) treated with BI 456906 withdrew from dose escalation due to adverse events (amylase increase, n = 1; decreased appetite, n = 9), and the proportion of participants was higher in DG 2 (n = 6, 66.7%) versus DGs 1 and 3 (both n = 2, 22.2%). No participants receiving placebo withdrew from dose escalation. BI 456906 exposure increased with dose and dose escalation in each DG. Treatment with BI 456906 decreased placebo-corrected bodyweight after 16 weeks (placebo +1.06%): DG 1, −5.57%; DG 2, −12.37%; DG 3, −9.62%. Paracetamol absorption decreased in Week 1 for DGs 2 and 3, indicating transient delayed gastric emptying. BI 456906 reduced plasma alanine and glucagon levels, indicating indirect target engagement at GCGRs and GLP-1Rs. Drug-related adverse events were reported for all participants receiving BI 456906 and four receiving placebo, the most frequent being decreased appetite (n = 24, 66.7%).Conclusions
BI 456906 showed no unexpected tolerability concerns and it reduced placebo-corrected bodyweight by up to 12.37% in Japanese men with overweight/obesity after 16 weeks of treatment. 相似文献15.
Søren Snitker MD PhD Andreas Andersen PhD Birgitte Berg MSc Sjoerd van Marle MD Thomas Sparre MD PhD 《Diabetes, obesity & metabolism》2021,23(6):1415-1419
This double-blind, randomized, single-site, crossover trial compared the injection-site experience with the starting doses of semaglutide and dulaglutide. Healthy subjects (aged 18–75 years; body mass index ≥ 25 kg/m2; n = 104) were randomized 1:1, using a pregenerated list, to semaglutide 0.25 mg as the first injection and dulaglutide 0.75 mg as the second injection or vice versa; each was administered using their proprietary pen-injectors, according to instructions for use. The primary endpoint was intensity of injection-site pain, measured using a visual analogue scale (VAS; 0 mm = no pain, 100 mm = unbearable pain). Exploratory endpoints included intensity category, duration and quality of injection-site pain, and comparative assessment of injection-site pain with the two injections. The point estimate of the VAS score for injection-site pain intensity was 11.5 mm with dulaglutide versus 5.6 mm with semaglutide; mean (95% confidence interval) estimated treatment difference 5.9 (3.6; 8.2) mm; p < .0001. Other endpoints corroborated a less painful injection experience with semaglutide versus dulaglutide. Safety was consistent with reported data for the drugs. In conclusion, the injection-site experience with semaglutide was rated as less painful than that with dulaglutide. 相似文献
16.
17.
Juan P. Frias MD Enzo Bonora MD David A. Cox PhD M. Angelyn Bethel MD Anita Y.M. Kwan MSc Sohini Raha PhD Raleigh E. Malik PhD 《Diabetes, obesity & metabolism》2021,23(12):2819-2824
The AWARD-11 trial demonstrated the safety and efficacy of dulaglutide 3.0 and 4.5 mg compared to dulaglutide 1.5 mg in patients with type 2 diabetes inadequately controlled with metformin. This post hoc analysis examined the change from baseline in glycated haemoglobin (HbA1c) and proportions of patients achieving HbA1c <7% at weeks 36 and 52 with dulaglutide 1.5 mg, 3.0 mg or 4.5 mg across clinically relevant baseline HbA1c subgroups (<8%; 8.0% to < 9.0%; 9.0% to < 10%; and ≥ 10%). Mean reductions in HbA1c were observed across all baseline HbA1c subgroups at 36 weeks (range of HbA1c change: 1.5 mg: −1.0% to −2.2%; 3.0 mg: −1.2% to −2.5%; and 4.5 mg: −1.2% to −3.2%). More patients randomized to 3.0 mg or 4.5 mg (vs. 1.5 mg) achieved HbA1c <7% at 36 weeks regardless of baseline HbA1c; the difference in proportions was greater at higher baseline HbA1c (P-interaction = 0.096). Similar patterns in glycaemic improvement and proportions achieving HbA1c <7% were observed at 52 weeks. Hypoglycaemia and gastrointestinal adverse events were similar among the HbA1c subgroups. Glycaemic control was improved with dulaglutide dose escalation from 1.5 mg to 3.0 mg or 4.5 mg across baseline HbA1c subgroups (<8%; 8.0% to < 9.0%; 9.0% to < 10%; and ≥ 10%). 相似文献
18.
19.